Surgical devices maker Conmed's Q3 sales rise 6.7%, slightly beating estimates

Conmed

05/11/2025 21:59

Overview

Conmed Q3 sales rose 6.7% yr/yr, slightly beating analysts' expectations

Adjusted EPS for Q3 was $1.08, beating analysts' expectations

Company authorized $150 mln share repurchase program, and suspended quarterly cash dividend

Outlook

Conmed expects full-year revenue between $1.365 bln and $1.372 bln

Company anticipates full-year adjusted EPS of $4.48 to $4.53

Conmed estimates tariffs to negatively impact Q4 EPS by $0.07

Result Drivers

SUPPLY CHAIN STRENGTH - CEO Patrick J. Beyer attributed Q3 performance to improvements in supply chain and execution across core growth platforms

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
Slight Beat*
$337.93 mln
$334.76 mln (6 Analysts)
Q3 Adjusted EPS
Beat
$1.08
$1.05 (6 Analysts)
Q3 EPS
$0.09
Q3 Net Income
$2.86 mln
Q3 Income from Operations
$11.88 mln
Q3 Pretax Profit
$4.27 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Conmed Corp is $61.00, about 25.1% above its November 4 closing price of $45.71

The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release: ID:nBw721dd8a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)